Tube Tug-of-War: keeping or removing drain during pancreatic surgery may cut complications

NCT ID NCT07532759

Not yet recruiting Knowledge-focused Sponsor: Xu'an Wang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces serious problems like bile leaks and other major complications within 90 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PTCD catheter (a drainage tube placed before surgery to relieve bile blockage)

What this could lead to

If this trial succeeds, it could guide surgeons on whether to keep or remove the PTCD tube during pancreatic surgery, potentially reducing serious complications like bile leaks.

What could go wrong

This is an early exploratory trial with only 100 participants, so results may not apply to all patients. The study compares two surgical approaches, not a new drug, so the impact is limited to surgical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract neoplasm Biliary Tract Neoplasms exocrine pancreatic carcinoma obstructive jaundice periampullary adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••